So-Young International Inc. American Depository Shares - SY STOCK NEWS

So-Young International Inc. (NASDAQ: SY) announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the Securities and Exchange Commission on April 25, 2023. The report is accessible on the company’s investor relations website. Shareholders and ADS holders can obtain a hard copy of the annual report, which contains audited financial statements, by request. As a leader in China's medical aesthetics social community, So-Young provides reliable information and vetted services to users, aiming to expand within the medical aesthetic industry and the growing consumption healthcare market.

So-Young International Inc. (Nasdaq: SY) reported unaudited financial results for Q4 and FY 2022, revealing total revenues of RMB325.1 million (US$47.1 million) for Q4, down 27.7% year-over-year. The company achieved a net income of RMB31.3 million (US$4.5 million), reversing a loss of RMB27.7 million in Q4 2021. However, FY 2022 revenues declined 25.7% to RMB1,257.9 million (US$182.4 million), with a net loss of RMB65.6 million (US$9.5 million) compared to a loss of RMB8.4 million in FY 2021. The company holds a solid cash balance of RMB1.6 billion, providing potential growth opportunities in 2023. Looking ahead, So-Young expects Q1 2023 revenues between RMB290 million (US$42.0 million) and RMB310 million (US$44.9 million).

So-Young International Inc. (NASDAQ: SY) has announced it will report its financial results for the fourth quarter and full year ended December 31, 2022, on March 21, 2023. The earnings conference call will take place at 7:30 AM U.S. Eastern Time. This report will provide insights into the company's performance in the medical aesthetics industry, the largest social community in China. Investors can access a live and archived webcast of the call via the company's investor relations website.

So-Young International Inc. (Nasdaq: SY) has announced its compliance with Nasdaq's minimum bid price requirement of US$1.00 per share, effective January 4, 2023. Previously notified of non-compliance on July 15, 2022, the Company regained compliance after the closing bid price remained above US$1.00 for 11 consecutive business days from December 16, 2022, to January 3, 2023. Nasdaq has deemed this matter closed, which is a positive development for the Company.

So-Young International Inc. (Nasdaq: SY) has increased its Share Repurchase Program from US$15 million to US$25 million. This decision reflects the Company's confidence in its long-term prospects within the expanding medical aesthetics market. The program is effective for 12 months starting from November 18, 2022, allowing repurchases in various market conditions. So-Young aims to fund these repurchases from its cash balance, highlighting its commitment to enhancing shareholder value.

So-Young International Inc. (SY) reported its Q3 2022 financial results, revealing total revenues of RMB323.3 million (US$45.5 million), a 25.1% decline year-over-year. The company recorded a net income of RMB2.3 million (US$0.3 million), down from RMB6.8 million in Q3 2021. The decrease in revenues was attributed to challenges posed by COVID-19. Despite a 28.1% year-over-year increase in paying medical service providers to 6,199, active monthly users dropped to 3.9 million from 8 million a year earlier. The board authorized a US$15 million share repurchase program to enhance shareholder value.

So-Young International Inc. (NASDAQ: SY) will release its financial results for Q3 2022 on November 18, 2022, prior to U.S. market opening. Following this, an earnings conference call is scheduled for 7:00 AM ET the same day, with dial-in options for international, U.S., and China callers. The call will be accessible via a live and archived webcast on the company's investor relations website. So-Young continues to serve as a leading social community in China for the medical aesthetics sector, fostering a trustworthy platform for users.

So-Young International Inc. (Nasdaq: SY) announced the immediate withdrawal of its non-binding going private proposal by Chairman and CEO Mr. Xing Jin. This decision follows a review of current market conditions, leading the board to dissolve the special committee overseeing the proposal. So-Young remains positioned as a leading social community in China's medical aesthetics industry, emphasizing its trusted platform and extensive service provider network.

So-Young International Inc. (SY) reported its second quarter financial results for 2022, showing total revenues of RMB309.1 million (US$46.1 million), down 31.6% year-over-year. The company posted a net loss of RMB32.3 million (US$4.8 million), a decline from a net income of RMB57.6 million in Q2 2021. Average mobile monthly active users fell to 3.5 million from 10 million a year ago. Despite challenges, the number of paying medical service providers grew by 17.1% to 5,735. For Q3 2022, So-Young anticipates revenues between RMB310 million and RMB330 million, indicating a continued decline from the previous year.